225 results about "Streptococcus bacteria" patented technology

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

The invention discloses application of epimedin A in preparation of a streptococcus suis type 2 capsule inhibitor, and belongs to the technical field of biological medicine. The compound can effectively inhibit the synthesis function of the streptococcus suis type 2 capsule, further enhances the removal effect of a host on the streptococcus suis type 2, reduces the pathogenicity of bacteria, and provides a new candidate compound and idea for preparing a capsule inhibitor of the streptococcus suis type 2 and researching and developing a novel medicine for treating streptococcus suis type 2 infection.

The invention discloses an application of marine streptomyces SH110 and a source compound thereof, the marine streptomyces SH110 has a preservation number of GDMCC (China General Microbiological Culture Collection Center) NO.66668, and the preservation date is July 14, 2025; the invention also discloses application of the marine streptomyces SH110-derived compound in preparation of a medicine for preventing and treating streptococcus and vibrio diseases. The marine streptomyces source compound has efficient vibrio and streptococcus resisting activity, the vibrio and streptococcus resisting activity is not reported, and the marine streptomyces source compound has new application. The marine streptomyces source compound is used for preparing the medicine for preventing and treating the vibrio and streptococcus diseases, especially for preparing the medicine for preventing and treating the vibrio and streptococcus diseases of aquaculture animals, the safety is high, and the treatment effect is good.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

Compositions comprising 5. salivarius strain SALI-10 and / or salivarius 10 peptide are taught. Also taught are methods of treating bacterial infections comprising administering a pharmaceutically acceptable amount of the composition to the patient with a bacterial infection caused by a pathogen from, for example, multi-drug resistant (MDR) Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus dysagalactiae, vancomycin-resistant Enterococcus faecium, Porphyromonas gingivalis, Tannerella forsythia, and MDR Enterococcus faecalis.

The invention belongs to the technical field of synthesis and antibiosis of nano-enzyme catalysis systems, and discloses an enzyme catalysis system with a function of targeted inhibition of growth of streptococcus mutans as well as preparation and application of the enzyme catalysis system. The enzyme catalysis system with the targeted inhibition function on the growth of the streptococcus mutans is formed by loading AuNPs and PCN-22 (Fe) on a CMD molecular chain through in-situ growth, and the mass ratio of the AuNPs to the PCN-22 (Fe) to the CMD is (0.22%-0.33%) to (12.34%-21.79%) to (77.88%-87.44%). The cascade catalytic effect of the nano-enzyme is adjusted by regulating and controlling the carboxymethyl substitution degree of CMD, so that glucose in a decayed tooth pathological environment is efficiently catalyzed in one step to generate ROS, and damage to probiotics is reduced while the inhibition efficiency of pathogenic bacteria is improved.

The present disclosure relates to a method for treating triple-negative breast cancer or non-muscle-invasive bladder cancer in a subject, comprising administering to the subject a composition comprising nonviable cells of Streptococcus pyogenes and an immune checkpoint inhibitor.

The invention relates to a preparation method and application of erythritol galactoside. The method specifically comprises the following steps: constructing a reaction system which takes o-nitrobenzene-beta-D-galactopyranoside as a glycosyl donor, erythritol as a receptor and recombinant beta-galactosidase Bga7 as a catalytic enzyme, so as to prepare the erythritol-beta-galactoside. Wherein the amino acid sequence of the beta-galactosidase Bga7 is as shown in SEQ ID No.2, and the nucleotide sequence of the beta-galactosidase Bga7 is as shown in SEQ ID No.1. The invention also provides an application of the erythritol-beta-galactoside in preparation of daily chemical products or medical preparations for resisting streptococcus mutans infection. The invention provides a novel beta-galactosidase Bga7 gene of a glycosidase family 2, and a novel tool enzyme is provided for synthesis of galactoside products. The erythritol-beta-galactoside prepared by the invention has good effects of preventing streptococcus mutans infection and caries, and can be used for preparing daily chemical products or medical preparations for preventing streptococcus mutans infection.

The invention discloses antibacterial mouthwash as well as a preparation method and application thereof, and belongs to the technical field of daily chemical products. According to the invention, egg white lysozyme, ferulic acid and grape seed procyanidine are taken as core components, and the mouthwash with an efficient bacteriostatic effect is developed. And the antibacterial rates of streptococcus mutans and porphyromonas gingivalis are 96.88% and 96.30% respectively. Researches show that bacterial biofilms can be destroyed by using the mouthwash, and the biofilm quantity is reduced by 53.7% after the bacterial biofilms are treated for 24 hours; extracellular polysaccharide is inhibited, the content of water-insoluble glucan is reduced by 62.3%, and synthesis of a key cariogenic matrix is hindered; the acid production capacity is regulated and controlled, the pH change of 24-hour culture is only 1.50, and xylitol competitively inhibits glycolysis and cooperates with ferulic acid to block bacterial metabolism. The mouthwash prepared by the invention avoids the problem of enzyme activity inhibition of the ionic surfactant of the traditional mouthwash, takes effect more quickly, and provides a basis for developing natural, safe and efficient functional mouthwash.

The present application belongs to the technical field of biological medicine, and particularly relates to a thiol phenylboronic acid mediated nano-enzyme immunochromatography reagent and application thereof. The present application utilizes the broad-spectrum binding ability of MPBA to the glycosylated molecules on the surface of pathogens, and combines the colorimetric catalytic double enhancement effect of the virus-like biomimetic magnetic nano-enzyme (FeAu@AuIr), to improve the detection sensitivity. The probe takes Fe3O4 magnetic nanoparticles as the core, and sequentially loads large-diameter gold nanoparticles (Au) and gold-iridium alloy (AuIr) with high catalytic activity, to enhance the pathogen capture capacity and signal amplification effect. Combined with the antibody modified immunochromatography strip, Streptococcus pneumoniae, Pseudomonas aeruginosa and SARS-CoV-2 can be simultaneously detected, and the detection sensitivity is greatly improved. Through verification of 170 clinical samples, the present application has good application prospect in on-site rapid detection, and provides an efficient and low-cost solution for precise screening of respiratory tract infectious pathogens.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

The invention discloses an application of SNF2 protein derived from streptococcus angina extracellular vesicles in gastric cancer prognosis. The chromatin remodeling protein SNF2 derived from S.anginosus EVs can be combined with a transcription factor TEAD1, so that the transcription of the palmitoyl transferase ZDHHC11 is promoted together. Then, the stability of the ZDHHC11 is enhanced by catalyzing palmitoylation of PD-L1, and finally immune escape is induced. In addition, SNF2 also can activate AXL, CTGF, CYR61 and other carcinogenic targets at the downstream of TEAD1, thereby further accelerating the malignant progression of gastric cancer. In an in-vivo experiment, the intragastric administration of the S.anginosus EVs not only promotes the tumor growth of mice, but also significantly inhibits the infiltration of CD8 + T cells. Blocking of ZDHHC11 can effectively reverse immune escape, and has a synergistic effect with an anti-PD-1 therapy, so that the treatment effect is remarkably improved.

Provided are Streptococcus salivarius and compositions comprising Streptococcus salivarius for the treatment of ENT diseases, in particular cancer therapy-induced oral mucositis and respiratory tract infections associated with cancer therapy.

In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.

A method for producing a fermented milk product (e.g. a yogurt) with a relatively high stable pH value at the end of the fermentation comprising inoculating milk with Streptococcus thermophilus (ST) Gal(+) bacteria.

The invention provides oral streptococcus ZRSOR-5 as well as a related product, a method and application thereof. The preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention in the Guangdong Microbial Culture Collection Center is GDMCC No: 65352, and the preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention is CGMCC No: 65352. Experiments prove that the SOR preparation is prepared by diluting the SOR preparation with normal saline and inhaling the SOR preparation into mice in advance, so that the survival rate of influenza virus infected mice can be remarkably increased, and lung inflammation and virus load can be reduced. When the ZRSOR-5 preparation provided by the invention is used in advance, pneumonia caused by influenza viruses can be resisted.

A chewable tablet a first probiotic strain of bacteria that inhibits Streptococcus mutans; a second probiotic strain of bacteria that inhibits one or more of Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia (i.e., the red complex); a remineralizing agent such as hydroxyapatite with a micron-level particle size; and a sugar alcohol such as xylitol.

The application discloses a freeze-drying protective agent for Streptococcus pneumoniae without animal source, and belongs to the field of microorganism preservation. The freeze-drying protective agent is composed of the following components: 1-5% (weight / volume) soybean peptone, 1-5% (weight / volume) trehalose, 4-8% (weight / volume) mannitol and 0.3-1.5% (volume / volume) glycerol, and the rest is water. The freeze-drying protective agent can better maintain the activity of Streptococcus pneumoniae, and the effect is equivalent to that of a skimmed milk protective agent or a commercially available freeze-drying protective agent without animal source, but the freeze-drying protective agent does not contain animal source components and has low cost.

The invention provides an antibacterial and anti-inflammatory traditional Chinese medicine compound preparation and a preparation method thereof. The compound preparation is prepared from the following raw materials in parts by weight: 10 to 30 parts of fructus forsythiae, 10 to 25 parts of flos chrysanthemi, 15 to 40 parts of rhizoma imperatae, 5 to 10 parts of herba menthae, 0.5 to 3 parts of borneol and 0.1 to 3 parts of camphor. The main innovation point of the formula is that triple mechanisms of clearing away heat and toxic materials, repairing mucous membranes and rapidly relieving pain are innovatively fused; instantaneous mucous membrane permeation is realized through volatile components (borneol, mint and camphor), and itching and pain are quickly relieved; forsythia suspense-chrysanthemum-couch grass root synergistically inhibit release of inflammatory factors and radically diminish swelling, and the specific functions are as follows: forsythia suspense has antibacterial and antiviral effects and inhibits streptococcus in throat; chrysanthemum has the effects of clearing liver fire, relieving heat toxin and eliminating mucosal hyperemia; the couch grass root can promote salivation, moisten dryness and repair damaged mucosa; mint is capable of quickly relieving itching and promoting transmembrane absorption of the medicine; borneol is used for instantly cooling and easing pain and opening a cell channel; and camphor and local anesthesia enhance the pain relieving time efficiency.

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

The invention discloses a beta-glucan composition for regulating skin micro-ecology as well as a preparation method and application thereof, and belongs to the technical field of cosmetics. The beta-glucan composition disclosed by the invention is prepared from the following components in percentage by mass: 0.2 to 0.6 percent of beta-glucan, 1 to 3 percent of a streptococcus thermophilus fermentation product and 0.05 to 0.15 percent of capryloyl hydroximic acid. The beta-glucan composition prepared by the invention is mild in formula and can achieve a rapid anti-inflammatory effect. By adopting the synergistic effect of the beta-glucan, the streptococcus thermophilus fermentation product and the capryloyl hydroximic acid, common adverse flora on the skin surface is inhibited, inflammatory factors are reduced, and the micro-ecological balance of the skin is rebuilt.

The present application relates to the technical field of caries-preventing gel, and particularly discloses a preparation method of sucrose-modified polyethylene glycol nanometer ferroferric oxide caries-preventing gel, wherein sucrose is used to modify ferroferric oxide, so that the adsorption of the material to bacteria is improved, and the killing capacity of the material to Streptococcus mutans is further improved compared with dextran material.The caries-preventing gel material has good biological safety, is not prone to drug resistance, has good acid-producing bacteria adsorption and killing effect on Streptococcus mutans; meanwhile, the material has a temperature-sensitive gel dosage form, has fluidity when stored at low temperature, forms a colloidal gel in an oral environment, can stay on the tooth surface for a long time, and effectively inhibits plaque microorganisms.

The invention belongs to the technical field of biomedicine, and particularly relates to a flora marker for predicting colorectal cancer liver metastasis and application of the flora marker. According to the present invention, the bacterial group marker is the combination of Acinetobacter, Streptococcus, Pseudomonas, Brevundimonas and Sphingomonas, and the bacterial group marker combination provides extremely high specificity (95.29%) and sensitivity (91.43%) when the early liver metastasis of colorectal cancer is predicted, such that the liver metastasis risk of the patient can be accurately assisted in the determination, and the early liver metastasis risk of the colorectal cancer can be accurately determined; the method has the advantages that reliable basis is provided for clinical decision making, the colorectal cancer liver metastasis can be predicted only by taking the abundance of the specific bacteria as an input index, the method is not limited by specific measurement means, and dependence on a detection technology is greatly reduced.

The present invention relates to a fusion protein, immunogenic composition, recombinant vaccine, and molecular architecture design and application, etc., for the prevention of Streptococcus Pneumoniae infection. The present invention starts from the protein molecular tertiary structures of ply and PhtD, and via creatively screening, the C-terminal domain of ply protein and the N-terminal domain of phtD protein are finally selected to construct a fusion protein, and the elements such as Fc domain and STABILON are further added. The fusion protein molecule of the present invention can weaken tissue lesions caused by Streptococcus Pneumoniae infection, has good immunogenicity, has an effective preventive and immunoprotective effect, and efficiently prevents Streptococcus Pneumoniae infection. The immunogenic composition, fusion protein, and recombinant vaccine for preventing Streptococcus Pneumoniae infection of the present invention have broad application prospects.

The invention discloses application of a series of isosteviol derivatives in preventing and treating pathogenic bacteria of cow mastitis, and belongs to the field of medicinal chemistry. According to the present invention, with the application of the derivative of the present invention, the excellent inhibition activity on the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 12386 and Streptococcus dysgalactiae ATCC 27957 can be provided, and the application of the derivative of the present invention provides the excellent inhibition activity on the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 12386 and Streptococcus dysgalactiae ATCC 27957, the synthesis method of the compound is simple, the raw materials are cheap and easy to obtain, and the compound has great development value in the aspect of natural product source compounds for preventing and treating cow mastitis. The structural formula of the compound is shown in the specification.

The present invention relates to streptococcal vaccine formulations and their use in generating immunity against streptococcal infection.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. The immunogenic compositions of the invention typically comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. The present invention also relates to the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection using said novel immunogenic compositions.

The invention relates to the technical field of biological detection, in particular to a nucleic acid combination product, a PCR premix, a method and a kit for identifying respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair as shown in SEQ ID NO: 1 to SEQ ID NO: 21 and a probe. The invention provides a nucleic acid detection product for detecting klebsiella pneumoniae, streptococcus pneumoniae, haemophilus influenzae, pseudomonas aeruginosa, acinetobacter baumannii, staphylococcus aureus and moraxella catarrhalis, and the nucleic acid detection product can be used for performing amplification detection on conserved fragments of target pathogens in the same PCR reaction system, and is efficient and low in cost. Moreover, the anti-interference capability is strong, and the sensitivity is high.

The invention relates to a group B streptococcus oligoglycoprotein conjugate as well as a preparation method and application thereof, and belongs to the technical field of group B streptococcus vaccine development. Inactivated group A streptococcus C5a peptidase ScpA193 is used as a carrier and is connected with group B streptococcus oligosaccharide antigens to prepare the group B streptococcus-resistant oligosaccharide protein conjugate, and the oligosaccharide antigens are oligosaccharide trisaccharide derivatives, oligosaccharide pentasaccharide derivatives or oligosaccharide octasaccharide derivatives of group B streptococcus cell wall surface polysaccharides. The oligosaccharide protein conjugate prepared by the invention can simultaneously induce two types of antibodies with different target spots to synergistically aim at group B streptococcus, and is a compound vaccine. The vaccine has better applicability, can more effectively inhibit group B streptococcus, and is not limited by the problem of bacterial drug resistance caused by use of a large amount of antibiotics.